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Chronic inflammatory diseases (CID) are emerging disorders which do not only affect
specific organs with respective clinical symptoms but can also affect various aspects of
life, such as emotional distress, anxiety, fatigue and quality of life. These facets of chronic
disease are often not recognized in the therapy of CID patients. Furthermore, the
symptoms and patient-reported outcomes often do not correlate well with the actual
inflammatory burden. The discrepancy between patient-reported symptoms and
objectively assessed disease activity can indeed be instructive for the treating physician
to draw an integrative picture of an individual’s disease course. This poses a challenge for
the design of novel, more comprehensive disease assessments. In this mini-review, we
report on the currently available patient-reported outcomes, the unmet needs in the field of
chronic inflammatory diseases and the challenges of addressing these.
Keywords: patient reported outcome (PRO), CID, IBD, precision medicine, rheumatology, mobile devicesINTRODUCTION - LIMITATIONS OF THE CURRENT DISEASE
ACTIVITY MEASURES
Chronic inflammatory diseases (CID) such as inflammatory bowel disease (IBD), rheumatoid
arthritis (RA) and psoriasis are chronic inflammatory disorders at various interfaces of the human
body, which, however, do not only lead to organ-specific manifestations, but indeed show strong
overlaps of sites of inflammation, including the corresponding clinical symptoms. For all specific
diseases, disease activity scores have been developed (e.g., SLEDAI for systemic lupus erythematodes
(SLE), PASI for psoriasis). Each of these indices aim to capture organic inflammatory burden but inorg March 2021 | Volume 12 | Article 6146531
Tran et al. PROs in CIDa relevant proportion of patients they do not reliably reflect
disease activity quantified by imaging methods or invasive
diagnostics, such as endoscopy in IBD. In rheumatoid arthritis
(RA), even in clinical remission or low disease activity (as defined
by DAS28) about 1/3 of patients is reported to have ongoing
synovitis on histological and molecular level (1). The fact, that
most of these indices are complex composite scores, including
laboratory values, patient’s self-assessment, symptoms, and
objective measures (such as the CDAI for Crohn’s disease)
emphasizes the difficulties in thoroughly capturing the
complexity of disease manifestation. In particular, subclinical
inflammatory burden in beginning flares or insufficient disease
control is hardly detectable (or distinguishable from unspecific
symptoms with non-inflammatory etiology), raising the need for
adequate methods for screening of these seemingly hidden
disease processes. Thus, also the diagnosis of CID can be
challenging if the symptoms are overseen as exemplified by the
underdiagnosis of psoriasis-arthritis (PsA) by about 15% in
patients with psoriasis (2), even though this population of risk
(with a lifetime incidence of 6-42% of developing PsA) is easy to
identify since skin manifestations precede joint disease in most of
the cases.
As CID are incurable diseases and typically have an onset in
young or mid-aged adults, the patients and providers need to
find individual therapeutic and monitoring strategies for this
problem for many decades. Unresolved chronic inflammation
leads to chronic destruction of affected tissues, such as synovial
tissue, cartilage and bone in RA. The current disease activity
scores elude to describe or quantify the grade of irreversible
tissue destruction, which accumulates over time if the
inflammation is not properly controlled and accounts for long-
term impairments of physical and social function. The Patient’s
and Physician’s Global Assessment (PaGA/PhGA) can give a
hint toward possible impairments with a higher sensitivity (3)
and are thus integrated in a few scores (such as the CDAI for RA,
Mayo score for ulcerative colitis), but still do not capture all
possible symptoms (like psychological co-morbidities) or reflect
the specific problems in the necessary granularity.
Beyond the somatic disease activity, CID also affect various
aspects of life, e.g. quality of life, fatigue or social functioning and
should thus be taken into account in treatment decisions by
physicians (4). Of note, significant patient-physician discordance
of disease activity is a frequently reported phenomenon (5, 6).
This discrepancy may significantly reduce the likelihood of
reaching remission in composite-scores used for measurement
of disease activity, which complicates the application of treat-to-
target approaches (7). Major non-inflammatory factors
contributing to such discordance and, thus, complicating the
interpretation of disease activity measures and reducing the
likelihood of remission defined by composite scores are co-
morbidities like fatigue, chronified pain-syndromes, anxiety
and depression (7–9).
Therefore, in addition to objective measures (such as
laboratory results) as well as the PhGA and PaGA, objectified
and specified self-evaluations of disease, co-morbidities and
social impairments are important to improve medical care.Frontiers in Immunology | www.frontiersin.org 2PROS: HOW CAN THE PATIENT’S VIEW
HELP US IN ASSESSING THEIR
DISEASES?
Addressing this lack of structured assessment, patient-reported
outcomes (PROs) are standardized and validated instruments
that generate numerical data representing the patients’
perception and view on the burden of a disease and its
treatment (e.g., symptoms, disease course, treatment effects)
(10–13). PROs have been developed in research settings but
are increasingly used in clinical practice and considered an
essential part of comprehensive patient assessment.
Additionally, shared decision making is an important part of
modern therapeutic strategies (14, 15).
Longitudinal use of PROs may help tracking the patient’s
perspective (e.g. regarding quality of life, disease activity,
functional capacity, psychological health) over the course of
the disease or in response to treatment modifications (10, 13).
In shared decision making, PROs are one pillar of
therapy guidance.
Conceptually, PRO instruments can be categorized into
generic or disease-specific measures (10). Generic measures do
not target a specific disease type but can be applied across
different diseases and thus, allow cross-disease comparisons.
Generic PROs assess, for example, overall quality of life
(established and often used instruments are e.g., EuroQoL, SF-
12 and SF-36) and focus on general aspects like self-care, mobility,
and physical and mental function (10). Classically, PROs can be
subdivided into different domains addressing different areas of life
and disease symptoms i.e. fatigue, pain, depressive symptoms,
movement disabilities, which are probably the biggest domains
that need to be covered.
However, and different to classical objective measures of
disease activity, PROs might be influenced by many other
factors, as e.g., by other co-existing diseases, psychological
disorders that are not related to the disease of interest, social or
financial problems (16).
Disease-specific PRO measures are constructed for a specific
patient population, a specific disease, functions or symptoms (10).
A number of disease-specific PROs have been developed for
different chronic inflammatory disease conditions, including
IBD (17) and rheumatic disease conditions (18). Most of the
questions in these disease-specific PROs target a respective organ
system and related symptoms. In IBD, for instance, bowel
movements, bloody stool and abdominal pain are obvious
questions, and PROs for rheumatoid arthritis center around
functional capacity, and pain.PROS IN RHEUMATOLOGY
In rheumatology, international consortia have been formed to
foster the development of PROs. OMERACT (“Outcome
Measures in Rheumatology”) is such an initiative (19) which
recommends measures that meet certain predefined criteria (e.g.March 2021 | Volume 12 | Article 614653
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PROs in rheumatology are described below.
Many PROs contain one question related to the overall disease
activity or the overall health, which can be rated by the patient on
a Visual Analogue Scale (as a PaGA) (20). PaGA correlates
moderately with more objective measures of disease activity,
but is also influenced by non-rheumatic factors, such as
education or the cultural background of a patient (5, 20).
Because PaGA mostly focus on the disease activity in the form
of symptoms and pain at the main organ side (e.g. the joints), they
rarely sufficiently assess the systemic disease process which
includes systemic inflammation driving somatic (e.g. vascular
and metabolic disease) as well as psychological impairments.
PaGA is incorporated in classical disease scores, such as Disease
Activity Score with 28-joint count (DAS28) or Simplified Disease
Activity Index (SDAI), both used in rheumatoid arthritis, and is,
therefore, already part of a more comprehensive assessment
approach (21).
High rates of anxiety and depression (about 10 to 40%) have
been reported in RA and PsA (9, 22) using standardized screening
instruments such as Patient Health Questionnaire (PHQ)-9 or
Hospital Anxiety andDepression Scale (HADS) which have overall
well diagnostic performance in rheumatic joint diseases (23). Many
patients in remission as determined by DAS28 have persisting
pain, pointing on one hand toward the pathophysiology of chronic
joint pain in rheumatic diseases and on the other hand toward the
insufficiency of end-point definitions without PROs (24). Classical
PROs used in rheumatology are scores such as HAQ-DI, which
focusses on activities of daily life. Other PROs used in rheumatoid
arthritis (RA) are the Routine Assessment of Patient Index Data-3
(RAPID-3; covering pain, PaGA and functional impairment) and
the Rheumatoid Arthritis Impact of Disease (RAID) instrument
(covering pain, functional disability, fatigue, emotional well-being,
sleep, coping and physical well-being) (25, 26).
The Psoriatic Arthritis Impact of Disease (PsAID)
questionnaire is an instrument to measure impact of the disease
(PsA) on different domains and dimensions of the patient’s health
(27), including pain, fatigue, skin problems, social participation,
and work and/or leisure activities (27). Further questionnaires, like
the Toronto Psoriatic Arthritis Screening (ToPAS) tool (28), the
Psoriasis Epidemiology Screening Tool (PEST) (29), the Psoriatic
Arthritis Screening and Evaluation (PASE) (30) and the Early
Psoriatic Arthritis Screening Questionnaire (EARP) (31), have
been established to target the need for early detection/screening of
disease processes, and their relevance have been independently
validated (2, 32). PROs have been incorporated in recent therapy
goal definitions and activity scores, exemplified by the Minimal
Disease Activity (MDA, containing the HAQ) (33) and the
PASDAS (including SF-36 questionnaire) (34).PROS IN INFLAMMATORY BOWEL
DISEASE
Similar to other chronic inflammatory disease conditions, IBD is
characterized by relevant perception gaps between providers andFrontiers in Immunology | www.frontiersin.org 3patients, both for intestinal symptoms and social or functional
impact of disease (35–37). The available most comprehensive
measures for disease activity are the Crohn’s Disease Activity
Index (CDAI) for Crohn’s disease and the Mayo score for
ulcerative colitis. The CDAI, for instance, is a complex
composite score but does not reflect impact of disease in the
patient’s daily life (38). The patient reported 2-item (PRO2) and
3-item (PRO3) are sub-scores of the CDAI, that cover stool
frequency, the presence of abdominal pain and include the
patient’s general well-being (PRO3) (39) and are currently
increasingly used in clinical trials. However, many available
PROs might correlate well with other composite disease scores
(e.g. PRO2/3 correlates well with CDAI), but do not with
objective disease activity markers, such as endoscopic scores or
stool biomarkers of inflammation (40–42). Therefore, an
important goal is to develop PROs that correlate better and
more consistently with endoscopy-defined disease activity.
However, even improved PROs will not completely bridge the
discrepancies of symptoms and endoscopic disease activity and
thus need to be regarded as important cornerstones but not the
exclusive therapy guidance parameters.
In another approach to create a more comprehensive PRO
which covers both perceived disease activity and classical
patient-reported functionality, a simple, rapid tool to measure
disease control from the patient’s perspective was developed and
validated in 2013 - the IBD-control questionnaire (43). This
questionnaire comprises 13 items with the four core domains
physical, social, and emotional functioning, and treatment as
well as a VAS (43). Other disease-specific PROs to measures e.g.
disease-specific quality of life (IBDQ) (44), fatigue (IBD-F) (45)
and disability (IBD disability index) (46, 47) in patients with IBD
are also available. The IBDQ considers intestinal symptoms,
systemic symptoms, social aspects, and emotional aspects (44)
and the IBD disability index covers body function, body
structures, activities and participation, and environmental
factors (46, 47). Also a range of generic PROs are commonly
applied in IBD patients including instruments that measure
depression and anxiety (BDI, HADS, PHQ-9) (48–53), and
sleep quality (PSQI) (54, 55). These PROs have also been
acknowledged as useful measures, complementary to and
correlating with the CDAI or Mayo score, to produce a
comprehensive disease assessment in clinical trial and real life
settings (56, 57). In IBD patients, major depression is present in
~9% and major anxiety in ~18% (52). The PHQ-9 had the
highest sensitivity (95%) in detecting depression and suicide
ideation in a validation study among other available PROs and
thus can be used as a good screening tool for depression (58), as
these co-manifestations of IBD are definitely undertreated (59).
In different European countries, such as Denmark, the
Netherlands and the UK, as well as in the US, e-Health tools
for the monitoring of IBD have been developed, with some of
them being directly linked to the health care system (60). With
the use of such e-Health applications, patients can receive
treatment recommendations online and the treating physician
can decide – upon review of the results of the PRO that has been
completed online – whether it is required to see the patient inMarch 2021 | Volume 12 | Article 614653
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might also be unnecessary if the results of the online PRO
indicate that the patient’s disease is currently inactive.PROS AND COMORBIDITIES
Besides the direct disease-related inflammatory burden and
symptoms, other co-morbidities (either prognostically
complicating disorders or diseases as consequences of long-
lasting CID or independent co-morbidities) need to be more
involved into the patient’s assessment as they are associated
with poorer patient-reported functional status in CID. In
multimorbid patients with RA the proportion of care by
rheumatology specialists is reduced (61), and thus the
incorporation of the treatment of several co-morbidities
is increasingly reflected in multidisciplinary treatment
recommendations (62). The age-adjusted Charlson Comorbidity
Index (CCI(A)) is a possible tool to assess co-morbidities (63)
and has been used in oncology (64) and COVID-19 (65, 66) to
predict long-term outcomes. The HAQ/HAQ-DI includes
physical impairments which is an established link between
perception of pain, cardiovascular and mental health (67, 68),
delivering a more comprehensive picture of the individual’s
everyday life, while distinguishing disability due to disease
activity from co-morbidity can be difficult in CID. Thus, better
tools to assess the individual role of co-morbidities need to
be developed.
The association of the organic comorbid “collateral damages”
of chronic inflammation and neuropsychiatric dysfunctions can
be mechanistically linked in an immunological manner (69).
Inflammatory cytokines can lead to persistent changes in CNS
immunity, subsequently facilitating alterations in CNS function
and thus i.e. skew emotional states toward depression (70). In
parallel, chronic systemic inflammation leads to metabolic
changes favoring accelerated atherosclerosis (71, 72) and
dyslipidemia (73).ARE PROS COMMONLY USED IN
CLINICAL PRACTICE?
PROs are important tools to monitor and document the patient’s
health state in clinical trial settings to compare outcomes
between treatment groups, without information on individual
patient’s results. In clinical practice, PROs could be used as
accurate and quantitative measures of the individual patient’s
needs, providing an extra layer of information besides the clinical
assessment to guide the long-term therapy (74). Despite the
potential of PROs to improve healthcare in CID and to foster
shared decision-making, they have not been broadly
implemented in the clinical routine. To overcome this,
pioneering efforts promoted the increasing use of PROs in the
clinical routine in certain regions, such as Denmark, by using
eHealth applications (60). However, some PRO measures are
relatively comprehensive (covering multiple different domains)Frontiers in Immunology | www.frontiersin.org 4and require a significant time effort by the patient to fill them out.
Therefore, shorter but reliable tools should be developed to
increase the response rate and to decrease the time and effort
required to complete them (13). Based on this approach,
validated short forms of several questionnaires have been
developed, e.g. the short IBDQ (SIBDQ) and PROMIS short
forms with 5-10 items, to increase the feasibility of multiple
assessments in longitudinal trials and clinical practice. The main
limitations, however, are shifts in the response pattern to PROs,
which might develop over time in an individual patient due to
conditioning to the questionnaires and coping with own
symptoms (response-shift bias) (75).
The implementation of web-based assessments like electronic
questionnaires represents another way to further promote the
use of PROs and to save time and resources (10, 13). Simple
compound scores could be used more often and could thus play a
role as part of online tracking tools for patients. By monitoring
their disease activity online with a simple scoring system, added
up by increasingly available point-of-care-tests (POCT), such as
fecal calprotectin, can help to evaluate disease activity in a setting
like the current COVID-19 pandemic. Furthermore, information
from PROs can be used as a trigger to initiate further
examinations, e.g. additional laboratory analyses. For example,
fatigue correlates with inflammatory activity and iron deficiency
in IBD patients (76). Thus, if IBD patients report fatigue, this
might guide the treating physician toward further iron tests or
more comprehensive assessment of disease activity.
The structured collection of longitudinal and cross-sectional
data might also contribute to identifying (novel) PROs for
disease prediction. Patient-reported scores have revealed to be
predictive of flares of specific diseases [e.g. multiple sclerosis
(77)] and, indeed, flare specific questionnaires have been
developed for some diseases (78). The most important point,
however, is that PROs allow us, to some extent, to identify and
address the disparity between the physician’s global assessment
that is far more attached to objective measures of inflammation
and the patient’s perception of disease activity. In a setting, where
shared decision making is the norm, this will help us to set
common ground and to define common goals beyond the pure
clinical definition of remission.WHAT ARE THE FUTURE NEEDS FOR
PROS?
Defining multidimensional measures for disease activity and co-
morbidities based on PROs, physician assessment, imaging
studies and molecular markers remains a challenge for the
future management of chronic inflammatory diseases (79). The
optimal PRO needs to either capture the inflammatory burden
(even if subclinical), disease-related symptoms/co-morbidities or
challenging disabilities in everyday life or identify patients at risk
for disease progress. Examples of such evolving PROs are the
IBD-Control and the RAID instrument.
More systematically use of PROs might be promoted by the
technical advances and digitalization efforts in healthcare andMarch 2021 | Volume 12 | Article 614653
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tests (80). Widespread use of waiting room devices, patient
“disease activity apps” and further development and use of
disease-specific POCT (“inflammometers”) could improve
CID healthcare.
The further development of wearable devices, which can track
vital signs, motion, stress and sleeping behavior in a real-time
fashion give rise to the question, whether this considerable
amount of patient data can be integrated in “Next Generation
PROs”. These wearables are subjects of ongoing trials in patients
with neurodegenerative disorders (81). A particular example is
the assessment of fatigue, which correlates well with disease
activity. In-depth assessment via questionnaires could be related
to different motion parameters to identify potential device-
derived disease activity measures such as reduced daily
exercise, and first trials already hint toward the benefits of
device-driven therapy guidance (82).
Combining these patient-centered measures with provider’s
assessments (including laboratory measures, imaging methods)
to an integrative disease activity profile might be the key for
precision medicine in CID care.CONCLUSIONS
PROs are important for clinical management and research, as
they represent a cornerstone of more personalized approaches inFrontiers in Immunology | www.frontiersin.org 5medicine. However, depending on the specific disease entity, the
available PROs only partially reflect actual disease activity as
assessed by more objective criteria like endoscopic scores.
The development and usage of PROs capturing disease activity
more precise for individual therapy guidance is crucial
and thus they need to be implemented more widely in
clinical routine.AUTHOR CONTRIBUTIONS
FT, IR, WL and BH conceptualized and drafted the initial
manuscript. All authors reviewed and revised the manuscript.
All authors contributed to the article and approved the
submitted version.FUNDING
This research was supported by the DFG ExC 2167 Precision
Medicine in Chronic Inflammation, and the EU Innovative
Medicine Initiative 2 Joint Undertaking (“3TR”, grant
agreement no. 831434; “ImmUniverse”, grant agreement no.
853995). We thank all contributors of the discussion on this
within the International Symposium of the ExC. We thank
Simon Imm for critical reading of the manuscript.REFERENCES
1. Orange DE, Agius P, DiCarlo EF, Mirza SZ, Pannellini T, Szymonifka J, et al.
Histologic and Transcriptional Evidence of Subclinical Synovial
Inflammation in Patients With Rheumatoid Arthritis in Clinical Remission.
Arthritis Rheumatol (2019) 71:1034–41. doi: 10.1002/art.40878
2. Iragorri N, Hazlewood G, Manns B, Danthurebandara V, Spackman E.
Psoriatic arthritis screening: a systematic review and meta-analysis.
Rheumatol (Oxford) (2019) 58:692–707. doi: 10.1093/rheumatology/key314
3. Kaneko Y, Kuwana M, Kondo H, Takeuchi T. Discordance in global
assessments between patient and estimator in patients with newly
diagnosed rheumatoid arthritis: associations with progressive joint
destruction and functional impairment. J Rheumatol (2014) 41:1061–6.
doi: 10.3899/jrheum.131468
4. Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life:
Results of the European Federation of Crohn’s and Ulcerative Colitis
Associations (EFCCA) patient survey. J Crohns Colitis (2007) 1:10–20.
doi: 10.1016/j.crohns.2007.06.005
5. Guimaraes M, Pinto M, Resende GG, Machado CJ, Vargas-Santos AB,
Amorim RBC, et al. Discordance between the patient’s and physician’s
global assessment in rheumatoid arthritis: Data from the REAL study-
Brazil. PLoS One (2020) 15:e0230317. doi: 10.1371/journal.pone.0230317
6. Challa DN, Kvrgic Z, Cheville AL, Crowson CS, Bongartz T, Mason TG 2nd,
et al. Patient-provider discordance between global assessments of disease
activity in rheumatoid arthritis: a comprehensive clinical evaluation. Arthritis
Res Ther (2017) 19:212. doi: 10.1186/s13075-017-1419-5
7. Michelsen B, Kristianslund EK, Hammer HB, Fagerli KM, Lie E, Wierod A,
et al. Discordance between tender and swollen joint count as well as patient’s
and evaluator’s global assessment may reduce likelihood of remission in
patients with rheumatoid arthritis and psoriatic arthritis: data from the
prospective multicentre NOR-DMARD study. Ann Rheum Dis (2017)
76:708–11. doi: 10.1136/annrheumdis-2016-2102838. Boyden SD, Hossain IN, Wohlfahrt A, Lee YC. Non-inflammatory Causes of
Pain in Patients with Rheumatoid Arthritis. Curr Rheumatol Rep (2016)
18:30. doi: 10.1007/s11926-016-0581-0
9. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in
rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol
(Oxford) (2013) 52:2136–48. doi: 10.1093/rheumatology/ket169
10. Black N. Patient reported outcome measures could help transform healthcare.
BMJ (2013) 346:f167. doi: 10.1136/bmj.f167
11. Wagner LI, Wenzel L, Shaw E, Cella D. Patient-reported outcomes in phase II
cancer clinical trials: lessons learned and future directions. J Clin Oncol (2007)
25:5058–62. doi: 10.1200/JCO.2007.11.7275
12. U.S. Department of Health and Human Services FDA Center for Drug
Evaluation and Research, U.S. Department of Health and Human Services
FDA Center for Biologics Evaluation and Research and U.S. Department of
Health and Human Services FDA Center for Devices and Radiological Health
Guidance for industry: patient-reported outcome measures: use in medical
product development to support labeling claims: draft guidance. Health Qual
Life Outcomes (2006) 4:79. doi: 10.1186/1477-7525-4-79
13. Weldring T, Smith SM. Patient-Reported Outcomes (PROs) and Patient-
Reported Outcome Measures (PROMs). Health Serv Insights (2013) 6:61–8.
doi: 10.4137/HSI.S11093
14. van Egdom LSE, de Kock MA, Apon I, Mureau MAM, Verhoef C, Hazelzet
JA, et al. Patient-Reported Outcome Measures may optimize shared decision-
making for cancer risk management in BRCA mutation carriers. Breast
Cancer (2020) 27:426–34. doi: 10.1007/s12282-019-01033-7
15. Schuler CL, Dodds C, Hommel KA, Ittenbach RF, Denson LA, Lipstein EA.
Shared decision making in IBD: A novel approach to trial consent and timing.
Contemp Clin Trials Commun (2019) 16:100447. doi: 10.1016/
j.conctc.2019.100447
16. Chang EM, Gillespie EF, Shaverdian N. Truthfulness in patient-reported
outcomes: factors affecting patients’ responses and impact on data quality.
Patient related outcomemeasures (2019) 10:171–86. doi: 10.2147/PROM.S178344March 2021 | Volume 12 | Article 614653
Tran et al. PROs in CID17. El-Matary W. Patient-reported outcome measures in inflammatory bowel
disease. Can J Gastroenterol Hepatol (2014) 28:536–42. doi: 10.1155/2014/792386
18. Orbai AM, Bingham CO3rd. Patient reported outcomes in rheumatoid
arthritis clinical trials. Curr Rheumatol Rep (2015) 17:28. doi: 10.1007/
s11926-015-0501-8
19. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an
international initiative to improve outcome measurement in rheumatology.
Trials (2007) 8:38. doi: 10.1186/1745-6215-8-38
20. Nikiphorou E, Radner H, Chatzidionysiou K, Desthieux C, Zabalan C, van
Eijk-Hustings Y, et al. Patient global assessment in measuring disease activity
in rheumatoid arthritis: a review of the literature. Arthritis Res Ther (2016)
18:251. doi: 10.1186/s13075-016-1151-6
21. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the
Clinical Disease Activity Index (CDAI): a review of their usefulness and
validity in rheumatoid arthritis. Clin Exp Rheumatol (2005) 23:S100–8.
22. McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A,
et al. Depression and anxiety in psoriatic disease: prevalence and associated
factors. J Rheumatol (2014) 41:887–96. doi: 10.3899/jrheum.130797
23. Hitchon CA, Zhang L, Peschken CA, Lix LM, Graff LA, Fisk JD, et al. Validity
and Reliability of Screening Measures for Depression and Anxiety Disorders
in Rheumatoid Arthritis. Arthritis Care Res (Hoboken) (2020) 72:1130–9.
doi: 10.1002/acr.24011
24. Lee YC, Cui J, Lu B, Frits ML, Iannaccone CK, Shadick NA, et al. Pain persists
in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a
longitudinal observational study. Arthritis Res Ther (2011) 13:R83.
doi: 10.1186/ar3353
25. Berthelot JM. RAPID3? Aptly named! Clin Exp Rheumatol (2014) 32:S-0-4.
26. Salaffi F, Di Carlo M, Vojinovic J, Tincani A, Sulli A, Soldano S, et al. Validity
of the rheumatoid arthritis impact of disease (RAID) score and definition of
cut-off points for disease activity states in a population-based European cohort
of patients with rheumatoid arthritis. Joint Bone Spine (2018) 85:317–22.
doi: 10.1016/j.jbspin.2017.05.020
27. Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, et al. A patient-
derived and patient-reported outcome measure for assessing psoriatic
arthritis: elaboration and preliminary validation of the Psoriatic Arthritis
Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative.
Ann Rheum Diseases (2014) 73:1012. doi: 10.1136/annrheumdis-2014-205207
28. Gladman DD, Schentag CT, Tom BD, Chandran V, Brockbank J, Rosen C,
et al. Development and initial validation of a screening questionnaire for
psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann
Rheum Dis (2009) 68:497–501. doi: 10.1136/ard.2008.089441
29. Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an
existing screening tool for psoriatic arthritis in people with psoriasis and the
development of a new instrument: the Psoriasis Epidemiology Screening Tool
(PEST) questionnaire. Clin Exp Rheumatol (2009) 27:469–74.
30. Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE
questionnaire: pilot-testing a psoriatic arthritis screening and evaluation
tool. J Am Acad Dermatol (2007) 57:581–7. doi: 10.1016/j.jaad.2007.04.001
31. Tinazzi I, Adami S, Zanolin EM, Caimmi C, Confente S, Girolomoni G, et al.
The early psoriatic arthritis screening questionnaire: a simple and fast method
for the identification of arthritis in patients with psoriasis. Rheumatol (Oxford)
(2012) 51:2058–63. doi: 10.1093/rheumatology/kes187
32. Mease PJ, Palmer JB, Hur P, Strober BE, Lebwohl M, Karki C, et al. Utilization
of the validated Psoriasis Epidemiology Screening Tool to identify signs and
symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional
analysis from the US-based Corrona Psoriasis Registry. J Eur Acad Dermatol
Venereol (2019) 33:886–92. doi: 10.1111/jdv.15443
33. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in
psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis
(2010) 69:48–53. doi: 10.1136/ard.2008.102053
34. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-
Duffin K, et al. The development of candidate composite disease activity and
responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis
(2013) 72:986–91. doi: 10.1136/annrheumdis-2012-201341
35. Rubin DT, Siegel CA, Kane SV, Binion DG, Panaccione R, Dubinsky MC,
et al. Impact of ulcerative colitis from patients’ and physicians’ perspectives:
Results from the UC: NORMAL survey. Inflamm Bowel Dis (2009) 15:581–8.
doi: 10.1002/ibd.20793Frontiers in Immunology | www.frontiersin.org 636. Schreiber S, Panes J, Louis E, Holley D, Buch M, Paridaens K. Perception gaps
between patients with ulcerative colitis and healthcare professionals: an online
survey. BMC Gastroenterol (2012) 12:108. doi: 10.1186/1471-230X-12-108
37. Schreiber S, Panes J, Louis E, Holley D, Buch M, Paridaens K. National
differences in ulcerative colitis experience and management among patients
from five European countries and Canada: an online survey. J Crohns Colitis
(2013) 7:497–509. doi: 10.1016/j.crohns.2012.07.027
38. Bojic D, Bodger K, Travis S. Patient Reported Outcome Measures (PROMs) in
Inflammatory Bowel Disease: New Data. J Crohns Colitis (2017) 11:S576–85.
doi: 10.1093/ecco-jcc/jjw187
39. Khanna R, Zou G, D’Haens G, Feagan BG, Sandborn WJ, Vandervoort MK,
et al. A retrospective analysis: the development of patient reported outcome
measures for the assessment of Crohn’s disease activity. Aliment Pharmacol
Ther (2015) 41:77–86. doi: 10.1111/apt.13001
40. Zittan E, Kabakchiev B, Kelly OB, Milgrom R, Nguyen GC, Croitoru K, et al.
Development of the Harvey-Bradshaw Index-pro (HBI-PRO) Score to Assess
Endoscopic Disease Activity in Crohn’s Disease. J Crohns Colitis (2017)
11:543–8. doi: 10.1093/ecco-jcc/jjw200
41. Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, et al. Poor
Correlation Between Clinical Disease Activity and Mucosal Inflammation,
and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease.
Am J Gastroenterol (2016) 111:541–51. doi: 10.1038/ajg.2016.59
42. van Andel EM, Koopmann BDM, Crouwel F, Noomen CG, de Boer NKH, van
Asseldonk DP, et al. Systematic Review of Development and Content Validity
of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do
We Measure What We Measure? J Crohns Colitis (2020) 14:1299–315.
doi: 10.1093/ecco-jcc/jjaa057
43. Bodger K, Ormerod C, Shackcloth D, Harrison M. Development and
validation of a rapid, generic measure of disease control from the patient’s
perspective: the IBD-control questionnaire. Gut (2014) 63:1092–102.
doi: 10.1136/gutjnl-2013-305600
44. Rose M, Fliege H, Hildebrandt M, Körber J, Arck P, Dignass A, et al.
Validierung der deutschsprachigen Version des ,,Short Inflammatory Bowel
Disease Questionnaire” (SIBDQ). Zs-Gastro (2000) 38:277–85. doi: 10.1055/s-
2000-14868
45. Czuber-Dochan W, Norton C, Bassett P, Berliner S, Bredin F, Darvell M, et al.
Development and psychometric testing of inflammatory bowel disease fatigue
(IBD-F) patient self-assessment scale. J Crohns Colitis (2014) 8:1398–406.
doi: 10.1016/j.crohns.2014.04.013
46. Peyrin-Biroulet L, Cieza A, SandbornWJ, Coenen M, Chowers Y, Hibi T, et al.
Development of the first disability index for inflammatory bowel disease based
on the international classification of functioning, disability and health. Gut
(2012) 61:241. doi: 10.1136/gutjnl-2011-300049
47. Lo B, Prosberg MV, Gluud LL, Chan W, Leong RW, van der List E, et al.
Systematic review and meta-analysis: assessment of factors affecting disability
in inflammatory bowel disease and the reliability of the inflammatory bowel
disease disability index. Aliment Pharmacol Ther (2017). doi: 10.1111/
apt.14373
48. Janmohamed N, Steinhart AH. Measuring Severity of Anxiety and Depression
in Patients with Inflammatory Bowel Disease: Low Concordance Between
Patients and Male Gastroenterologists. Inflamm Bowel Dis (2017) 23:1168–73.
doi: 10.1097/MIB.0000000000001107
49. Yamamoto-Furusho JK, Sarmiento-Aguilar A, Garcıá-Alanis M, Gómez-
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